Abivax S.A.
ABVX
Hisse Senetlerindeki Sıralama
#2373
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Hisse Fiyatı
$92.59
Piyasa Değeri
$8.08B
Değişim (1 gün)
-2.25%
Değişim (1 yıl)
4.78%
Ülke
FR
Ticaret Abivax S.A. (ABVX)
Kategori
Healthcare
Abivax S.A. (ABVX) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $94.75 - 2026-10-01
Gün sonu en düşük fiyat: $23.10 - 2015-06-01
Gün sonu en düşük fiyat: $23.10 - 2015-06-01
Abivax S.A. için hisse fiyatı geçmişi: 2015 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | -6.03% |
| 2025 | 1,503.20% |
| 2024 | -26.43% |
| 2023 | 60.28% |
| 2022 | -77.75% |
| 2021 | -2.30% |
| 2020 | 54.91% |
| 2019 | 56.94% |
| 2018 | 22.67% |
| 2017 | 47.19% |
| 2016 | -57.07% |
| 2015 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $763.31 | 8.49% |
CH
|
